Company Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients.
It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC).
The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.
In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
| Country | United States |
| Founded | 1999 |
| IPO Date | Jul 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Paul-Peter Tak |
Contact Details
Address: 117 Kendrick Street, Suite 450 Needham, Massachusetts 02494 United States | |
| Phone | 617 916 5445 |
| Website | candeltx.com |
Stock Details
| Ticker Symbol | CADL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001841387 |
| CUSIP Number | 137404109 |
| ISIN Number | US1374041093 |
| Employer ID | 52-2214851 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer |
| Charles Schoch | Interim Chief Financial Officer, Principal Accounting Officer, Treasurer and Secretary |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical and Development Officer |
| Ileen B. Winick | Chief People Officer |
| Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
| Dr. William Garrett Nichols M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 144 | Filing |
| Mar 18, 2025 | 144 | Filing |
| Mar 18, 2025 | 144 | Filing |
| Mar 17, 2025 | 144 | Filing |
| Mar 17, 2025 | 144 | Filing |
| Mar 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 8-K | Current Report |